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Abstract A naturally processed and presented ligand that is
shared by human leukocyte antigen (HLA) B*4402, B*4403
and B*4405 molecules has been identi¢ed in peptides isolated
from immunoa⁄nity puri¢ed HLA B44 complexes. This peptide
derived from HLA DPK residues 46^54, an endogenous product
of HLA DP expressed in the cell line Hmy2.C1R, is a prom-
inent peptide in the mass spectra of species isolated as bound
peptides from each allele when the three HLA B44 subtypes
were introduced as transfected gene products. Recombinant
truncated forms of HLA B*44051276, HLA B*44031276,
HLA B*44021276 and L2-microglobulin have been prepared
as inclusion bodies in Escherichia coli and refolded in the pres-
ence of the DPK4654 peptide and puri¢ed by a combination of
size exclusion and anion exchange chromatography. This mate-
rial was determined to be correctly folded based on detection of
a conformational epitope recognized by the W6/32 monoclonal
antibody. Large, plate-like crystals of the three complexes were
produced using polyethylene glycol as the precipitant. All the
crystals belong to the space group P212121 with unit cell dimen-
sions of approximately a=51, b=82, c=110 A7 . The crystals of
three B44/DPK complexes di¡racted to a resolution of 1.9 A7 or
better. For the ¢rst time, using this natural, high abundance
ligand of the HLA B44 molecules we have successfully ex-
pressed and refolded the three HLA B44 molecules and pro-
duced crystals amenable to structural studies. ; 2002 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
Key words: X-ray crystallography; HLA;
Mass spectrometry; Protein structure; Polymorphism;
Peptide ligand
1. Introduction
Human leukocyte antigen (HLA) molecules are cellular re-
ceptors that bind peptide antigens within specialized intracel-
lular environments, prior to transport to the cell surface where
they can interact with the T cell receptor (TcR) on T cells.
Class I HLA molecules typically bind short peptides 8^11
amino acids in length in the lumen of the endoplasmic retic-
ulum (ER) as heterodimers of class I heavy chain and the
monomorphic L2-microglobulin light chain. This complex of
class I heterodimers and peptide is then transported via the
Golgi apparatus to the cell surface where the peptide antigen
is presented to the TcR on the surface of cytotoxic T lympho-
cytes (CTLs). The recognition of this class I complex by CTLs
can result in the destruction of the antigen presenting cell
(APC). Since class I molecules are expressed by all nucleated
cells and the source of peptides that bind to class I molecules
is typically from endogenous sources, CTL-mediated killing of
APC is most relevant in the context of anti-tumor and anti-
viral immunity as well as transplantation (both graft versus
host disease and solid graft rejection).
The overall structure of class I molecules has been well
documented; however, high resolution structures that reveal
the di¡erent modes of peptide binding and peptide speci¢city
continue to provide critical information regarding the struc-
ture and function of these molecules. The HLA B44 family of
alleles is an important family of HLA molecules that are
found in around 24% of Caucasian individuals [1]. There is
no structure for any members of this family nor a structural
explanation for the selection of ligands (P2 Glu, P9 Phe/Tyr)
by these molecules [2,3]. HLA B*4405 di¡ers from other
members of the HLA B44 family by 1^2 amino acids, yet it
displays very di¡erent behavior in terms of antigen presenta-
tion. The amino acid residues that di¡er between these alleles
occur at position 156 (Asp in HLA B*4402 and B*4405 and
Leu in HLA B*4403) and position 116 (Asp in HLA B*4402
and B*4403 and Tyr in HLA B*4403) and have previously
been linked to di¡erential association to the transporter asso-
ciated with antigen presentation (TAP) molecule, a translocon
responsible for the transport of antigenic peptide precursors
from the cytoplasm to the lumen of the ER [4]. Thus, com-
pared to HLA B*4402 and B*4403 (the two most prevalent
alleles of this family), HLA B*4405 is able to present antigen
more rapidly [5] and exhibits tapasin independence [6] for
antigen loading and surface expression. This does not appear
to be due to the acquisition of higher a⁄nity ligands or en-
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hanced thermostability of the complex [6]. We therefore
sought evidence for a structural basis of these important im-
munological features of HLA B*4405 relative to the other
alleles and investigated the role of the polymorphic amino
acids at positions 116 and 156 in this context. In this report
we document the successful isolation of a common peptide
ligand from three HLA B44 alleles (4402, 4403, 4405), the
use of this peptide to direct the refolding of recombinant
HLA B*4402, B*4403 and B*4405 in vitro, as well as the
puri¢cation, crystallization and preliminary analysis of each
complex.
2. Materials and methods
2.1. Expression, refolding and puri¢cation
Recombinant HLA B44 was expressed in Escherichia coli as inclu-
sion bodies as described in [7]. The class I heavy chain was modi¢ed
by the removal of the leader sequence, transmembrane region and
cytosolic tail (amino acids 1^276 of the mature protein sequence).
cDNA encoding this region was ligated into the bacterial expression
vector pET, and transformed into the BL21 (RIL) strain of E. coli. At
an A600 of 0.6, cultures were induced with 1 mM of isopropyl-1-thio-
L-D-galactopyranoside (IPTG) for 12 h, bacteria were lysed in 50 mM
Tris^HCl pH 8.0, 1% Triton X-100, 1% sodium deoxycholate, 100 mM
NaCl and 10 mM dithiothreitol (DTT). Inclusion bodies were isolated
by centrifugation then washed with 50 mM Tris^HCl, 0.5% Triton
X-100, 100 mM NaCl, 1 mM NaEDTA, 1 mM DTT pH 8.0, and
washing in 50 mM Tris^HCl, 1 mM NaEDTA, 1 mM DTT pH 8.0,
and then solubilized in 25 mM MES, 8 M urea, 10 mM NaEDTA pH
6.0 with the protease inhibitors 1 Wg/ml Pepstatin A and 200 WM
phenylmethylsulfonyl £uoride (PMSF). Recombinant protein (60 mg
HLA B44 heavy chain and 20 mg L2m) was refolded with 30 mg of
the DPK4654 peptide (EEFGRAFSF) in the presence of 3 M guani-
dine^HCl, 10 mM Na acetate, and 10 mM NaEDTA pH 4.2, over 24 h
in 0.1 M Tris, 2 mM EDTA, 400 mM L-arginine^HCl, 0.5 mM oxi-
dized glutathione, 5 mM reduced glutathione pH 8.0 at 4‡C. Follow-
ing refolding, protein was dialyzed overnight against Milli Q using a
6^8000 kDa MWCO dialysis membrane (Spectrum, CA, USA). Pro-
tein was puri¢ed as a single peak by fast protein liquid chromatog-
raphy using ion exchange on a DE52 column (Whatman, Maidstone,
Kent, UK), size exclusion on a Superdex 75 pg gel ¢ltration column
(Amersham Pharmacia Biotech, Uppsala, Sweden), and a ¢nal ion
exchange on a Mono Q HR column (Amersham Pharmacia Biotech).
Following each puri¢cation step, protein was concentrated using
Millipore 5K NMWL membrane centrifugal ¢lter devices (Millipore,
Bedford, MA, USA) and sterile-¢ltered. Quantitative analysis was
based on comparisons to bovine serum albumin protein standards
using SDS^PAGE. Protein was concentrated to 3 mg/ml for use in
crystallization trials.
2.2. Qualitative analysis of B44 peptide complexes by capture
enzyme-linked immunosorbent assay (ELISA)
The conformational integrity of the B44 peptide complexes was
probed using a L2-microglobulin-dependent, conformation-sensitive
monoclonal antibody, W6/32 [8]. Refolded complexes of HLA
B*4402, B*4403 and B*4405 were veri¢ed by use in a capture ELISA
with W6/32 and a monoclonal antibody for human L2-microglobulin
as described previously [9]. Brie£y, 96-well round-bottom Maxisorp
immunoplates (Nunc, Denmark) were coated overnight at 4‡C with
20 Wg/ml of W6/32 in 0.5 M carbonate bu¡er, then washed in 0.05%
Tween 20 in phosphate-bu¡ered saline (PBS) and blocked for 1 h with
1% BSA at 37‡C. After washing, refolded complexes for each of the
three alleles were then serially diluted in 0.1 M Tris pH 8.0 and bound
to the plate for 1 h at 37‡C. Plates were washed and incubated with
horseradish peroxidase-labeled anti-human L2m (Dako, Carpinteria,
CA, USA; 1:5000; 0.5% BSA) for 1 h. Plates were developed using
the substrate o-phenylenediamine in 0.05 M citrate bu¡er, pH 5.0 for
30 min at 37‡C. Plates were read at OD492 nm, and results were calcu-
lated as the mean of triplicate analyses.
2.3. Crystallization
All crystallization trials were conducted using the hanging drop
vapor di¡usion technique using 24-well tissue culture plates. The crys-
tals were grown by mixing equal volumes of 3 mg/ml HLA B44^pep-
tide complex with the reservoir bu¡er (20^30% PEG 4K, pH 5.2^5.9,
0.1 M citrate, 0.2 M ammonium acetate) at room temperature. Each
well contained 1 ml of reservoir bu¡er. Large plate-like crystals ap-
peared within 1^5 days. The crystals were £ash-frozen prior to data
collection using 10% glycerol as the cryoprotectant.
2.4. Crystallography
All data were collected in-house on an R-Axis IV++ detector with
CuKK X-rays generated by a Rigaku RU-H3RHB rotating anode
generator and focused using Osmic mirrors. The frozen crystals
were collected using the inverse-P geometry. The di¡raction data
were processed and analyzed using D*TREK [10] and programs
from the CCP4 suite [11].
2.5. Cell lines and culture
The B-lymphoblastoid cell line Hmy2.C1R was generated by Q-ir-
radiation of a fast growing lymphoma LICR.LON.Hmy2 [12] and
selected with antibodies against HLA A and HLA B alleles and com-
plement. This resulted in a cell line with no detectable HLA A or B
gene products, but with intact antigen processing and presentation
pathways [13]. Thus, these cells are able to support high level expres-
sion of individually transfected HLA A, B or C gene products [13].
The individual transfection of HLA B*4402, B*4403 or B*4405 into
C1R was performed by electroporation (975 WF, 200 V) using a plas-
mid encoding the cDNA of each of the B44 molecules and a selectable
marker (pREP7) at a ratio 10:1. All cells were grown in RF-10
(RPMI 1640, Life Technologies, Gaithersburg, MD, USA) supple-
mented with 2 mM glutamine (Life Technologies), antibiotics, and
10% FBS (Commonwealth Serum Laboratories, Melbourne, Austra-
lia). For the peptide elution experiments cells were grown in 1 l roller
bottles in RF-10 with the appropriate selection. Flow cytometry was
used to establish that HLA B44 was stably expressed in the trans-
fected cell lines during expansion.
2.6. Puri¢cation of cell surface-associated HLA B44 complexes and
peptide analysis
Puri¢cation of HLA B44 complexes was performed as described
previously [14]. Brie£y, C1R.B*4402, C1R.B*4403 or C1R.B*4405
cells were grown in roller bottles to a density around 1U106 cells/
ml. Approximately 5U109 cells were lysed at 4‡C in 0.5% Nonidet
P-40, 20 mM Tris, and 150 mM NaCl (pH 7.4) supplemented with
Complete1 protease inhibitor cocktail (Roche). Cell lysates were
clari¢ed by centrifugation and the supernatant ¢ltered and passed
over a Tris-blocked Sepharose 4B precolumn. The precleared lysates
were then applied to a column containing 2 ml of W6/32 a⁄nity
matrix (prepared as described previously [14]) and the column was
washed in bu¡er containing 50 mM Tris, 150 mM NaCl, and
0.005% Nonidet P-40 (pH 8.0). The column was subsequently washed
extensively with 50 mM Tris and 150 mM NaCl (pH 8.0), a high salt
bu¡er (50 mM Tris and 500 mM NaCl (pH 8.0), and ¢nally with 50
mM Tris (pH 8.0). Bound HLA B44 peptide complexes were eluted
with 10% acetic acid, which also facilitates dissociation of the B44-
bound peptides. The eluate was then passed through a Centricon 3
membrane (Millipore), and the £ow-through was concentrated by
vacuum centrifugation to a ¢nal volume of approximately 300 Wl.
This material was then subjected to further puri¢cation with re-
versed-phase high-performance liquid chromatography (RP-HPLC)
using a Smart system HPLC (Pharmacia Biotech, Uppsala, Sweden).
Peptides were separated using a WRPC C2/C18 (2.1 mm (inside diam-
eter)U10 cm column; Pharmacia Biotech). Eluted peptides were re-
solved from contaminating detergent polymers by employing a rapid
gradient from 0 to 60% acetonitrile in 0.1% aqueous tri£uoroacetic
acid (TFA; 12%/min, 200 Wl/min). Further puri¢cation of the eluted
peptides was a¡orded using an optimized linear gradient from bu¡er
A (0.1% TFA) to 40% B (acetonitrile/0.09% TFA; 1.3%/min), then
40% B to 60% B (4%/min) at a £ow rate of 200 Wl/min was used to
separate peptides. Fractions (150 Wl) were retained and analyzed by
matrix-assisted laser desorption/ionization time-of-£ight mass spec-
trometry (MALDI-TOF MS; as described in Section 2.7).
2.7. Peptide synthesis, sequencing and mass spectrometry
Synthetic peptides were purchased from Mimotopes (Clayton, Aus-
tralia) and synthesized with free carboxyl and amino termini using
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PIN-based techniques (30). MALDI-TOF MS was performed using a
Bruker Re£ex mass spectrometer (Bruker, Bremen, Germany) oper-
ated exclusively in the re£ectron mode as described previously [15].
Aliquots of fractions (1^2 Wl) were mixed with an equal volume of
K-cyano-4-hydroxycinnamic acid (10 mg/ml in acetonitrile/ethanol,
1/1, v/v), spotted onto a target, and dried for analysis. Post-source
decay (PSD) experiments were performed using 14 stepwise decre-
ments in the re£ectron potential and increasing the laser irradiance
to optimize the production of fragment ions at each voltage. Identi-
¢cation of fragmented ion species was determined by assigning C- and
N-terminal ion series and comparing parent m/z and fragmentation
data to database entries using MS-FIT routines available through the
protein prospector program (http://prospector.ucsf.edu) [16]. Accurate
parent ion mass and fragmentation data allowed assignment of pep-
tide sequences, which were con¢rmed by fragmenting a synthetic ver-
sion of the peptide under identical conditions and comparison of the
mass-spectral ¢ngerprints.
3. Results and discussion
3.1. Isolation of HLA B44-bound peptides and analysis of a
common ligand
Peptides have previously been isolated from HLA B*4402
and HLA B*4403 and exhibit a canonical glutamic acid P2
motif, with either phenylalanine or tyrosine at P6 (i.e. C-ter-
minal amino acid residue) [2,17]. HLA B*4405 is a rarer sub-
type of this common Caucasian and Asian allelic family that
displays novel biochemical and immunochemical behavior,
including very rapid intracellular tra⁄cking [5] and lack of
dependence for the chaperone tapasin for antigen loading
([6] and Purcell et al., manuscript in preparation). Studies of
T cell cross-reactivity on these closely related HLA B44 sub-
types suggest that HLA B*4405 binds to an overlapping sub-
set of peptides compared to B*4402 and B*4403; however,
some di¡erences between these alleles are also evident
([1,5,18,19] and our unpublished data). In order to assess
the similarity in peptide repertoire of B*4405 to previously
reported ligands of B*4402 and B*4403 we isolated HLA
B*4405 complexes from the surface of transfected APC,
eluted peptides and analyzed the peptides by MALDI-TOF
MS. The peptide pools derived from each puri¢ed allele con-
tained a dominant species at (M+H)þ =1089.4 amu, which
was contained within a single RP-HPLC fraction (Fig. 1).
This peptide was subsequently sequenced by PSD in MAL-
DI-TOF MS and identi¢ed as an abundant self-peptide from
HLA DPK amino acid residues 46^54 (Fig. 2, spectra of pos-
itive polarity), the class II molecules also expressed by the
C1R cell line. A complex fragmentation pattern was observed
by MALDI-TOF PSD analysis due to the internal arginine
residue, which included the formation of characteristic inter-
nal ions that can complicate automated sequence assignment
[15]. To con¢rm the sequence assignment the fragmentation of
the retrospectively synthesized DPK peptide EEFGRAFSF
(Fig. 2, negative spectra) was compared to the natural ligand,
as shown in Fig. 2 (comparison of positive and negative spec-
tra) and Table 1; identical fragmentation patterns were ob-
served. This con¢rms unambiguously the sequence assign-
ment, since such fragmentation patterns act as molecular
¢ngerprints [20,21].
3.2. Expression and refolding of HLA B44 ^ peptide complexes
Given the apparent abundant nature of the DPK peptide
and the lack of any crystal structures for the B44 family of
alleles we decided to express and refold recombinant HLA
B44 complexed to this peptide (DPA1*0201 residues 46^54).
We hypothesized that an abundant natural ligand that sur-
vives the cell surface extraction and puri¢cation procedure is
most likely a high a⁄nity ligand suitable for structural stud-
Fig. 1. An example of the RP-HPLC separation of peptides isolated
from HLA B*4402 using WRPC C18 narrowbore (2.1 i.d. mmU10
cm) column and a linear gradient of 0^60% acetontrile in 0.1%
TFA is shown (upper ¢gure). Below is a region of the mass spectra
from a fraction containing a dominant species of m/z 1089.5 amu
that is common to eluates from all three B44 molecules (an ex-
panded region of the MALDI-TOF spectra of eluates is shown for
each allele).
Fig. 2. PSD analysis of the species with m/z=1089.5 amu isolated
from the three HLA B44 molecules (the species from B*4402 eluates
is shown as the spectra of positive polarity and was typical for the
PSD spectra for all three eluates). PSD in MALDI-TOF MS was
performed using 14 stepwise decrements in the re£ectron potential
and increasing the laser irradiance to optimize the production of
fragment ions at each voltage. Accurate parent ion mass and frag-
mentation data allowed assignment of peptide sequences, which
were con¢rmed by fragmenting a synthetic version (spectra of nega-
tive polarity) of the peptide under identical conditions and compari-
son of the mass-spectral ¢ngerprints.
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ies. cDNA for each HLA B44 allele was cloned into pET-
based vectors and a truncated form (amino acids 1^276) of
these heavy chains expressed as insoluble inclusion bodies in
E. coli strain BL21 (RIL). Cultures were induced with 1 mM
of IPTG for 12 h and inclusion bodies prepared according to
the method of Garboczi [7]. Recombinant protein (60 mg
HLA B44 heavy chain and 20 mg L2m) was refolded with 30
mg of the DPK4654 peptide (EEFGRAFSF) over 24 h in a
redox refolding bu¡er. Following refolding, protein was dia-
lyzed overnight against Milli Q water and puri¢ed to homo-
geneity by DEAE anion exchange chromatography, size ex-
clusion (Superdex 75) and a ¢nal Mono Q anion exchange
chromatographic step. Quantitative analysis of the puri¢ed
complex was based on comparisons to BSA protein standards
using SDS-PAGE (see Fig. 3A,B). The conformational integ-
rity of the refolded complexes was assessed by a capture ELI-
SA incorporating the conformationally sensitive monoclonal
Table 1
Assignment of fragment ions of a natural HLA B*4405 ligand
Table 2
Data collection statistics
B*4405
Temperature 100 K
Space group P212121
Cell dimensions (AT ) (a,b,c) 50.77, 82.23, 110.00
Resolution (AT ) 1.7
B*4402
Temperature 100 K
Space group P212121
Cell dimensions (AT ) (a,b,c) 50.8, 81.8, 110.1
Resolution (AT ) 1.6
B*4403
Temperature 100 K
Space group P212121
Cell dimensions (AT ) (a,b,c) 50.7, 82.1, 109.1
Resolution (AT ) 1.9
C
Fig. 3. A: SDS^PAGE separation of components of the recombi-
nant B*4402 complexes following ion exchange and size exclusion
puri¢cation steps. B: Size exclusion chromatogram of ion exchange-
puri¢ed recombinant HLA B*4402. The elution position of HLA
B*4402 complex was consistent with the elution position of stan-
dards, including other HLA^peptide complexes, indicating an appar-
ent molecular weight of approximately 45 kDa. C: Capture ELISA
using a conformation-sensitive monoclonal antibody reveals correct
conformation of refolded and puri¢ed HLA B44 complexes. Key:
8=B*4402/DPK, R=B*4403/DPK, F=B*4405/DPK, b=B8/
FLRGRAYGL.
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antibody W6/32 [8] ; as shown in Fig. 3C, each complex pos-
sessed the monoclonal antibody determinant and displayed
dose-dependent recognition, indicating that the recombinant
B44 complexes were in a native conformation. Protein was
concentrated to 3 mg/ml for use in crystallization trials.
3.3. Crystallization of three allelic variants of the
HLA B44^DPK4654 complex
In order to make structure-based observations regarding
the nature of allelic micropolymorphism and its in£uence on
ligand binding, each HLA B44 allele was individually refolded
and subjected to crystallization trials. Crystals were success-
Fig. 4. Photo microscopy of the crystals formed for the three B44^
DPK complexes. Each allele formed large plate-like crystals under
the conditions described in Section 2.3.
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fully grown by the hanging drop method using PEG 4000 as
the precipitant for each complex. The crystals were grown by
mixing equal volumes of 3 mg/ml HLA B44^peptide complex
with the reservoir bu¡er (20^30% PEG 4000, pH 5.2^5.9,
0.1 M citrate, 0.2 M ammonium acetate) at room tempera-
ture. Large plate-like crystals appeared within 1^5 days (see
Fig. 4). The crystals were £ash-frozen prior to data collection
using 10% glycerol as the cryoprotectant. The crystals belong
to space group P212121 with unit cell dimensions approxi-
mately a=51, b=82, c=110 (see Table 2 for individual sta-
tistics). The unit cell volume is consistent with one complex in
the asymmetric unit. The three crystals di¡ract to a resolution
of 1.9 AT or better. Structure determination is currently under-
way.
The high resolution structures of these three alleles will
represent the ¢rst report of the same peptide bound to
multiple human HLA molecules in a serological subfamily,
di¡ering from each other by 1^2 amino acids. We suggest
that the structures will provide insights into the role these
subtypes play in transplant rejection and also provide struc-
tural bases for the disparate intracellular behavior of these
molecules. Moreover, the HLA DPK peptide is derived
from a polymorphic human gene, and the region spanning
amino acids 46^54 contains a dimorphism (R50Q) depending
on the HLA DP allele. This suggests that this peptide may
also play a role as a minor histocompatibility antigen, one of
the major causes of chronic rejection in transplantation.
Thus, these structures have additional general interest and
the methods described herein for the production of recombi-
nant forms of these molecules have potential use in diagnos-
tics that use HLA tetramer-based approaches for example
[22].
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